Home LiteratureArticle Details
PMID: 23657835 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Seminars in immunopathology ·Vol. 35 ·No. 5 ·2013-09-00 ·Pages 585-600

Biswas SK, Allavena P, Mantovani A

Abstract

Inflammation is now a well-recognized hallmark of cancer progression. Tumor-associated macrophages (TAMs) are one of the major inflammatory cells that infiltrate murine and human tumors. While epidemiological studies indicate a clear correlation between TAM density and poor prognosis in a number of human cancers, transgenic studies and transcriptome profiling of TAMs in mice have established their crucial role in cancer progression. In fact, TAMs affect diverse aspects of cancer progression including tumor cell growth and survival, invasion, metastasis, angiogenesis, inflammation, and immunoregulation. New evidences have extended the repertoire of these cells to other tumor promoting activities like interactions with cancer stem cells, response to chemotherapy, and tumor relapse. These findings have triggered efforts to target TAMs and their associated molecules to modulate tumor progression. In particular, "re-education" to activate their anti-tumor potential or elimination of tumor promoting TAMs are strategies undergoing preclinical and clinical evaluation. Proof-of-principle studies indicate that TAM-centered therapeutic strategies may contribute to cancer therapy.

MeSH Terms
Animals Cytokines/immunology Disease Progression Genetic Variation/immunology Humans Inflammation/immunology Macrophage Activation/immunology Macrophages/immunology Mice Neoplasms/drug therapy,immunology
Chemicals
Cytokines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Biswas Subhra K
Singapore Immunology Network SIgN, Agency for Science, Technology & Research A*STAR, #04-01 Immunos, 8A Biomedical Grove, Singapore, 138648, Singapore. subhra_biswas@immunol.a-star.edu.sg
Allavena Paola
Mantovani Alberto
References (137)
137 references, click to expand
  1. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.
    Immunity. 2013 Jan 24;38(1):79-91 PMID: 23273845
  2. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated.
    Cancer Res. 2009 Jun 1;69(11):4800-9 PMID: 19458073
  3. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.
    Cancer Cell. 2008 Oct 7;14(4):299-311 PMID: 18835032
  4. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation.
    Eur J Immunol. 2011 Aug;41(8):2155-64 PMID: 21710478
  5. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.
    Blood. 2008 Jun 15;111(12):5457-66 PMID: 18375791
  6. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
    Cancer Cell. 2005 Sep;8(3):211-26 PMID: 16169466
  7. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.
    Cancer Cell. 2012 Apr 17;21(4):488-503 PMID: 22516258
  8. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
    Cell. 2004 Aug 6;118(3):285-96 PMID: 15294155
  9. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.
    Am J Pathol. 1997 May;150(5):1723-34 PMID: 9137096
  10. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Cancer Cell. 2011 Apr 12;19(4):512-26 PMID: 21481792
  11. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Science. 2011 Mar 25;331(6024):1612-6 PMID: 21436454
  12. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.
    Cancer Res. 2006 Dec 1;66(23):11432-40 PMID: 17145890
  13. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.
    J Exp Med. 2001 Mar 19;193(6):727-40 PMID: 11257139
  14. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.
    J Immunol. 2000 Jan 15;164(2):733-8 PMID: 10623817
  15. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.
    Neoplasia. 2009 Nov;11(11):1235-42 PMID: 19881959
  16. Altered macrophage differentiation and immune dysfunction in tumor development.
    J Clin Invest. 2007 May;117(5):1155-66 PMID: 17476345
  17. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  18. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  19. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.
    Am J Pathol. 2009 Mar;174(3):1048-64 PMID: 19218341
  20. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.
    Nature. 2008 Dec 11;456(7223):814-8 PMID: 18997773
  21. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
    Cancer Res. 2006 Apr 15;66(8):4349-56 PMID: 16618760
  22. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
    Cancer Cell. 2009 Aug 4;16(2):91-102 PMID: 19647220
  23. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.
    Lancet. 2012 Apr 28;379(9826):1602-12 PMID: 22440946
  24. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon.
    J Exp Med. 2012 Jan 16;209(1):139-55 PMID: 22231304
  25. Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
    J Clin Invest. 2007 Jan;117(1):175-84 PMID: 17200717
  26. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.
    Am J Pathol. 2002 Sep;161(3):947-56 PMID: 12213723
  27. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.
    Proc Natl Acad Sci U S A. 2010 May 4;107(18):8363-8 PMID: 20404138
  28. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
    Nature. 2012 Nov 8;491(7423):254-8 PMID: 23034650
  29. Intestinal lamina propria dendritic cell subsets have different origin and functions.
    Immunity. 2009 Sep 18;31(3):502-12 PMID: 19733097
  30. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
    Cell. 2006 Feb 24;124(4):823-35 PMID: 16497591
  31. A lineage of myeloid cells independent of Myb and hematopoietic stem cells.
    Science. 2012 Apr 6;336(6077):86-90 PMID: 22442384
  32. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis.
    J Natl Cancer Inst. 1994 Jan 19;86(2):120-6 PMID: 8271294
  33. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.
    J Exp Med. 1992 Jul 1;176(1):287-92 PMID: 1613462
  34. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor.
    Biochim Biophys Acta. 1986 Aug 5;865(1):59-67 PMID: 2425851
  35. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.
    Cancer Res. 2010 Jul 1;70(13):5270-80 PMID: 20530679
  36. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
    Nature. 2008 Jun 5;453(7196):807-11 PMID: 18432192
  37. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata.
    J Clin Invest. 2007 Jan;117(1):195-205 PMID: 17200719
  38. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
    Cancer Cell. 2012 Mar 20;21(3):309-22 PMID: 22439926
  39. Regulation of the chemokine receptor CXCR4 by hypoxia.
    J Exp Med. 2003 Nov 3;198(9):1391-402 PMID: 14597738
  40. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice.
    Cancer Res. 2005 Nov 15;65(22):10578-84 PMID: 16288051
  41. Role of macrophage targeting in the antitumor activity of trabectedin.
    Cancer Cell. 2013 Feb 11;23(2):249-62 PMID: 23410977
  42. Exploring the full spectrum of macrophage activation.
    Nat Rev Immunol. 2008 Dec;8(12):958-69 PMID: 19029990
  43. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
    Cell. 2010 Sep 3;142(5):699-713 PMID: 20813259
  44. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.
    J Immunol. 2005 Jul 15;175(2):1197-205 PMID: 16002723
  45. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.
    Blood. 2012 Oct 18;120(16):3280-7 PMID: 22948049
  46. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
    Cancer Res. 2010 Jul 15;70(14):5728-39 PMID: 20570887
  47. NF-kappaB: linking inflammation and immunity to cancer development and progression.
    Nat Rev Immunol. 2005 Oct;5(10):749-59 PMID: 16175180
  48. Colony-stimulating factor-1 in immunity and inflammation.
    Curr Opin Immunol. 2006 Feb;18(1):39-48 PMID: 16337366
  49. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  50. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
    J Clin Invest. 2011 May;121(5):1969-73 PMID: 21490397
  51. FcRgamma activation regulates inflammation-associated squamous carcinogenesis.
    Cancer Cell. 2010 Feb 17;17(2):121-34 PMID: 20138013
  52. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.
    Cell. 2005 Jul 1;121(7):977-90 PMID: 15989949
  53. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.
    Blood. 2007 Jun 15;109(12):5276-85 PMID: 17327411
  54. The chemokine system in diverse forms of macrophage activation and polarization.
    Trends Immunol. 2004 Dec;25(12):677-86 PMID: 15530839
  55. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  56. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation.
    Science. 2011 Jun 10;332(6035):1284-8 PMID: 21566158
  57. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
    J Pathol. 2002 Mar;196(3):254-65 PMID: 11857487
  58. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Immunol Rev. 2008 Apr;222:155-61 PMID: 18364000
  59. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
    Cancer Res. 2013 Feb 1;73(3):1128-41 PMID: 23221383
  60. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas.
    Clin Cancer Res. 2013 Apr 1;19(7):1670-80 PMID: 23363815
  61. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ.
    PLoS One. 2013;8(2):e56045 PMID: 23409120
  62. MSCs, macrophages, and cancer: a dangerous ménage-à-trois.
    Cell Stem Cell. 2012 Dec 7;11(6):730-2 PMID: 23217416
  63. Colony stimulating factors and myeloid cell biology in health and disease.
    Trends Immunol. 2013 Feb;34(2):81-9 PMID: 23000011
  64. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3.
    Cancer Cell. 2011 Apr 12;19(4):541-55 PMID: 21481794
  65. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
    Nat Med. 2013 Jan;19(1):57-64 PMID: 23202296
  66. The cell biology of macrophage activation.
    Annu Rev Immunol. 1984;2:283-318 PMID: 6100475
  67. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation.
    J Immunol. 2010 Jul 1;185(1):605-14 PMID: 20498354
  68. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression.
    J Immunol. 2006 Nov 15;177(10):7303-11 PMID: 17082649
  69. Origins of tumor-associated macrophages and neutrophils.
    Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6 PMID: 22308361
  70. Fate mapping analysis reveals that adult microglia derive from primitive macrophages.
    Science. 2010 Nov 5;330(6005):841-5 PMID: 20966214
  71. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes Dev. 2011 Dec 1;25(23):2465-79 PMID: 22156207
  72. Target validation using RNA interference in solid tumors.
    Methods Mol Biol. 2007;361:227-38 PMID: 17172715
  73. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.
    J Immunol. 2007 Feb 1;178(3):1357-62 PMID: 17237382
  74. Differential macrophage programming in the tumor microenvironment.
    Trends Immunol. 2012 Mar;33(3):119-26 PMID: 22277903
  75. Protective and pathogenic functions of macrophage subsets.
    Nat Rev Immunol. 2011 Oct 14;11(11):723-37 PMID: 21997792
  76. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.
    Genes Dev. 2010 Feb 1;24(3):241-55 PMID: 20080943
  77. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
    Lancet. 2012 Apr 28;379(9826):1591-601 PMID: 22440947
  78. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
    J Exp Med. 2009 Jun 8;206(6):1327-37 PMID: 19451266
  79. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
    Cancer Res. 2013 Jan 15;73(2):490-5 PMID: 23172310
  80. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
    Clin Cancer Res. 2000 Aug;6(8):3282-9 PMID: 10955814
  81. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients.
    Int J Cancer. 2009 Oct 1;125(7):1640-8 PMID: 19569243
  82. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Trends Immunol. 2002 Nov;23(11):549-55 PMID: 12401408
  83. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
    Cancer Res. 2010 Jan 1;70(1):68-77 PMID: 20028852
  84. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
    Cancer Cell. 2011 Jan 18;19(1):31-44 PMID: 21215706
  85. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  86. Expression of c-fos proto-oncogene in tumor-associated macrophages.
    J Immunol. 1990 Jun 15;144(12):4878-82 PMID: 2161881
  87. Macrophages regulate the angiogenic switch in a mouse model of breast cancer.
    Cancer Res. 2006 Dec 1;66(23):11238-46 PMID: 17114237
  88. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  89. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2.
    J Exp Med. 1994 Dec 1;180(6):2365-70 PMID: 7525853
  90. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.
    Int Immunopharmacol. 2011 Jul;11(7):862-72 PMID: 21251905
  91. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.
    J Clin Invest. 2009 Oct;119(10):3011-23 PMID: 19741298
  92. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
    Cancer Cell. 2010 Aug 9;18(2):160-70 PMID: 20708157
  93. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint.
    Eur J Immunol. 2012 Apr;42(4):957-74 PMID: 22531920
  94. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.
    PLoS One. 2012;7(12):e50946 PMID: 23284651
  95. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Cancer Res. 2010 May 1;70(9):3526-36 PMID: 20406969
  96. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα.
    Cell Stem Cell. 2012 Dec 7;11(6):812-24 PMID: 23168163
  97. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).
    Blood. 2006 Mar 1;107(5):2112-22 PMID: 16269622
  98. Tumour immunity: effector response to tumour and role of the microenvironment.
    Lancet. 2008 Mar 1;371(9614):771-83 PMID: 18275997
  99. Endotoxin tolerance: new mechanisms, molecules and clinical significance.
    Trends Immunol. 2009 Oct;30(10):475-87 PMID: 19781994
  100. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.
    Cancer Res. 2011 Feb 15;71(4):1263-71 PMID: 21303976
  101. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  102. Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
    Cancer Cell. 2005 Mar;7(3):211-7 PMID: 15766659
  103. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
    J Immunol. 2006 Apr 15;176(8):5023-32 PMID: 16585599
  104. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
    Nature. 2011 Jun 08;475(7355):222-5 PMID: 21654748
  105. HPV16 tumor associated macrophages suppress antitumor T cell responses.
    Clin Cancer Res. 2009 Jul 1;15(13):4391-400 PMID: 19549768
  106. Angiotensin II drives the production of tumor-promoting macrophages.
    Immunity. 2013 Feb 21;38(2):296-308 PMID: 23333075
  107. M-1/M-2 macrophages and the Th1/Th2 paradigm.
    J Immunol. 2000 Jun 15;164(12):6166-73 PMID: 10843666
  108. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
    Cancer Res. 2005 Apr 15;65(8):3437-46 PMID: 15833879
  109. Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10.
    Blood. 2012 Jan 5;119(1):227-37 PMID: 22058116
  110. Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice.
    BMC Immunol. 2011 Aug 04;12:43 PMID: 21813021
  111. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.
    BJU Int. 2011 Jun;107(12):1918-22 PMID: 21044246
  112. Are we ready to recommend aspirin for cancer prevention?
    Lancet. 2012 Apr 28;379(9826):1569-71 PMID: 22440945
  113. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors.
    J Immunol. 2001 Jun 1;166(11):6861-8 PMID: 11359846
  114. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
    J Clin Invest. 2010 Mar;120(3):694-705 PMID: 20179352
  115. Orchestration of metabolism by macrophages.
    Cell Metab. 2012 Apr 4;15(4):432-7 PMID: 22482726
  116. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.
    Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30 PMID: 21746895
  117. Macrophage plasticity and polarization: in vivo veritas.
    J Clin Invest. 2012 Mar;122(3):787-95 PMID: 22378047
  118. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression.
    Eur J Immunol. 2009 Aug;39(8):2126-35 PMID: 19609975
  119. Interactions between cancer stem cells and their niche govern metastatic colonization.
    Nature. 2011 Dec 07;481(7379):85-9 PMID: 22158103
  120. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
    BMC Cancer. 2012 Jul 23;12:306 PMID: 22824040
  121. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.
    Blood. 2010 Aug 5;116(5):829-40 PMID: 20404134
  122. Cancer immunoediting by the innate immune system in the absence of adaptive immunity.
    J Exp Med. 2012 Sep 24;209(10):1869-82 PMID: 22927549
  123. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages.
    J Immunol. 2000 Jan 15;164(2):762-7 PMID: 10623821
  124. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
    Br J Cancer. 2006 Aug 7;95(3):272-81 PMID: 16832418
  125. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  126. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior.
    Science. 2007 Aug 3;317(5838):666-70 PMID: 17673663
  127. Monocyte and macrophage heterogeneity.
    Nat Rev Immunol. 2005 Dec;5(12):953-64 PMID: 16322748
  128. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype.
    BMC Immunol. 2002 Jul 04;3:7 PMID: 12098359
  129. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships.
    Blood. 2009 Jul 23;114(4):901-14 PMID: 19383967
  130. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.
    Science. 2008 May 9;320(5877):807-11 PMID: 18467591
  131. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma.
    J Immunol. 1992 Feb 15;148(4):1280-5 PMID: 1737940
  132. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression.
    Cancer Res. 2000 Oct 15;60(20):5857-61 PMID: 11059783
  133. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response.
    Eur J Immunol. 2012 Jan;42(1):89-100 PMID: 22009685
  134. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
    N Engl J Med. 2010 Mar 11;362(10):875-85 PMID: 20220182
  135. "Re-educating" tumor-associated macrophages by targeting NF-kappaB.
    J Exp Med. 2008 Jun 9;205(6):1261-8 PMID: 18490490
  136. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms.
    J Immunol. 2008 Feb 15;180(4):2011-7 PMID: 18250403
  137. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
    Curr Opin Immunol. 2012 Apr;24(2):207-12 PMID: 22236695
Article Info
Journal
Seminars in immunopathology
Abbr.
Semin Immunopathol
ISSN
1863-2300
Published
2013-09-00
Epub
2013-00-09
Pages
585-600
Language
English
Region
Germany
NLM ID
101308769
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com